Benzamide, 4-methyl-N-[2,2,2-trichloro-1-[(4-chlorophenyl)thio]ethyl]-

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzamide, 4-methyl-N-[2,2,2-trichloro-1-[(4-chlorophenyl)thio]ethyl]-
• 英文别名: 4-methyl-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
• 化学式: C₁₆H₁₃Cl₄NOS
• 分子量: 409.2
• InChiKey: OCAGWVPJUUSEHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT
  申请人：Pulmatrix Operating Company, Inc.

  公开号：EP3470057A1

  公开（公告）日：2019-04-17

  The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.

  本发明涉及含有一种或多种二价金属阳离子（如钙）且含量小于 3% （按重量计）的可吸入干颗粒，以及含有这种可吸入颗粒的干粉。干粉颗粒可进一步含有活性剂，或用作输送活性剂的载体颗粒。
• Monovalent metal cation dry powders for inhalation
  申请人：Pulmatrix Operating Company, Inc.

  公开号：US10376465B2

  公开（公告）日：2019-08-13

  The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

  本发明针对的是用于全身给药或呼吸道给药的可吸入干粉和颗粒。干粉含有一种或多种单价金属阳离子（如 Na+），体积小且可分散。
• Methods for producing respirable dry powders
  申请人：Pulmatrix Operating Company, Inc.

  公开号：US10589039B2

  公开（公告）日：2020-03-17

  The invention related to dry powders that contain a therapeutic agent. The dry powders have characteristics, e.g., they are processable and/or dense in therapeutic agent that provide advantages for formulating and delivering therapeutic agents to patients.

  本发明涉及含有治疗剂的干粉。干粉具有可加工和/或富含治疗剂等特点，这些特点为配制治疗剂和向患者提供治疗剂提供了优势。
• Spider venom peptides and methods of use for modulating sodium channels
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：US10662229B2

  公开（公告）日：2020-05-26

  This invention relates to peptides and their use for modulating sodium channels. More particularly, the present invention relates to peptides from the venom of the tarantula Pamphobeteus nigricolor and their use in methods of inhibiting Nav1.7 and for treating or preventing conditions associated with Nav1.7 activity such as neuropathic, inflammatory and nociceptive pain.

  本发明涉及肽及其用于调节钠通道的用途。更具体地说，本发明涉及从狼蛛 Pamphobeteus nigricolor 的毒液中提取的肽及其在抑制 Nav1.7 的方法中的用途，以及在治疗或预防与 Nav1.7 活性相关的疾病（如神经性、炎症性和痛觉性疼痛）中的用途。
• Inhalable dry powders
  申请人：Pulmatrix Operating Company, Inc.

  公开号：US10806871B2

  公开（公告）日：2020-10-20

  The invention related to dry powders that contain a therapeutic agent. The dry powders have characteristics, e.g., they are processable and/or dense in therapeutic agent that provide advantages for formulating and delivering therapeutic agents to patients.

  本发明涉及含有治疗剂的干粉。干粉具有可加工和/或富含治疗剂等特点，这些特点为配制治疗剂和向患者提供治疗剂提供了优势。